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BACKGROUND: Doxorubicin and cyclophosphamide (AC) therapy is an effective treatment for early-stage breast cancer. Doxorubicin
is a substrate for ABCB1 and SLC22A16 transporters. Cyclophosphamide is a prodrug that requires oxidation to 4-hydroxy-
cyclophosphamide, which yields a cytotoxic alkylating agent. The initial oxidation is catalysed by cytochrome P450 enzymes including
CYP2B6, CYP2C9, CYP2C19 and CYP3A5. Polymorphic variants of the genes coding for these enzymes and transporters have been
identified, which may influence the systemic pharmacology of the two drugs. It is not known whether this genetic variation has an
impact on the efficacy or toxicity of AC therapy.
METHODS: Germ line DNA samples from 230 patients with breast cancer on AC therapy were genotyped for the following
SNPs: ABCB1 C1236T, G2677T/A and C3435T, SLC22A16 A146G, T312C, T755C and T1226C, CYP2B6*2, *8, *9, *3, *4
and *5, CYP2C9*2 and *3, CYP3A5*3 and CYP2C19*2. Clinical data on survival, toxicity, demographics and pathology were
collated.
RESULTS: A lower incidence of dose delay, indicative of less toxicity, was seen in carriers of the SLC22A16 A146G, T312C,
T755C variants. In contrast, a higher incidence of dose delay was seen in carriers of the SLC22A16 1226C, CYP2B6*2 and
CYP2B6*5 alleles. The ABCB1 2677A, CYP2B6*2, CYP 2B6*8, CYP 2B6*9, CYP 2B6*4 alleles were associated with a worse
outcome.
CONCLUSION: Variant alleles in the ABCB1, SLC22A16 and CYP2B6 genes are associated with response to AC therapy in the
treatment of breast cancer.
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Anthracycline-based adjuvant regimens have become the standard of
care for early-stage breast cancer in the United Kingdom. The regimen
of doxorubicin and cyclophosphamide (AC) is one of a number of
available choices, with widespread use in patients with an indication
for chemotherapy, but a low to moderate risk of recurrence. The
combination of doxorubicin and cyclophosphamide was first tested
by the National Surgical Adjuvant Breast and Bowel Project
as a simple alternative regimen to replace cyclophosphamide,
methotrexate and 5-fluorouracil (CMF), which had been establi-
shed as an effective adjuvant treatment (Fisher et al, 1990). In
1998, a meta-analysis of 11 randomised trials was published by the
Early Breast Cancer Trialists’ Collaborative Group, which explored
polychemotherapy in early breast cancer. From this, it was
apparent that anthracycline-containing combinations conferred a
statistically significant and clinically relevant advantage in survival
and recurrence compared with CMF (Early Breast Cancer Trialists’
Collaborative, 1998).
A number of factors are known to influence the response to AC
chemotherapy, including tumour stage, grade, number of lymph
nodes involved, oestrogen receptor (ER), progesterone (PR) and
ERBB2 expression (Clarke et al, 2008). However, possible pharma-
cological receptor influences on the response to adjuvant therapy
have not been widely considered. In particular, there have been few
investigations of the possible influence of variations in the genes
encoding transporters and drug metabolising enzymes relevant for
the two drugs. Doxorubicin is subject to transport by the ABCB1
transporter (Fairchild et al, 1987; Bradley et al, 1988; Leith et al,
1999) and by the solute transporter SLC22A16 (Okabe et al, 2005;
Lal et al, 2007). Cyclophosphamide is a prodrug activated by a
number of different cytochrome P450 enzymes, including CYP2B6
(Chang et al, 1993), CYP2C9, CYP2C19 (Chang et al, 1997) and
CYP3A5 (Roy et al, 1999). Each of these enzymes and transporter
genes is known to exhibit a degree of genetic variation, characte-
rised by single nucleotide polymorphisms (SNPs) (Ingelman-
Sundberg et al, 1999; Ariyoshi et al, 2001; Kim et al, 2001; Lal et al,
2007). These SNPs are present at significant frequencies in a
European population and their influence on the pharmacology of a
number of different agents has been characterised (Demorais et al,
1994; Aithal et al, 1999; Haas et al, 2004; Kimchi-Sarfaty et al,
2007).
The aim of this study was to examine the possible influence of
SNPs on the tolerance, side effects and overall clinical outcome of
AC chemotherapy in patients with breast cancer.
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A total of 230 patients were recruited to the study from 12th March
2002 until closure on 31st December 2007. All of the participants
were recruited from Medical Oncology outpatient clinics within the
Newcastle upon Tyne Hospitals NHS Foundation Trust and had
been treated with a combination of doxorubicin and cyclo-
phosphamide. This regimen comprises 60mgm
 2 doxorubicin
and 600mgm
 2 cyclophosphamide administered intravenously on
day 1 of each 21-day cycle, and repeated for a total of four or six
cycles. All patients gave written informed consent and the study
was given ethical approval by the Newcastle and North Tyneside
Research Ethics Committee I.
A 10ml blood sample from each patient was collected into an
EDTA-containing storage tube and whole blood samples were
stored at  201C before DNA extraction. Laboratory genotyping
analysis was performed on all samples for SNPs in the ABCB1,
SLC22A16, CYP2B6, CYP2C9, CYP2C19 and CYP3A5 genes (details
in Table 1). Clinical data were collected from patient notes and
from the Trust laboratory and Patient Administration Service
databases. Time to progression (TTP) and overall survival (OS)
data were collected at Medical Oncology outpatient clinics, where
patients attended 3-monthly from time of treatment to 2 years
follow-up, 6-monthly from 2 to 5 years and annually for up to
10 years.
Genotyping
DNA was purified from whole blood samples using a QIAmp Maxi
Blood kit (Qiagen, Crawley, UK). DNA yields were estimated
spectro photometrically using a Nanodrop ND-1000 (Nanodrop
Technologies, Wilmington, DE, USA). Genotyping for the
CYP2C9*2, CYP2B6*5, CYP2C19 and CYP3A5 SNPs was performed
by the commercially available Taqman Assays on Demand method
and genotyping of the SLC22A16 gene was performed by a custom-
designed Taqman assay as per the manufacturer’s instructions
(Applied Biosystems, Warrington, UK). The CYP2B6*2, *3 and *4
SNPs were determined using a previously described RFLP method
(Lang et al, 2001). The ABCB1, CYP2B6*8 and *9, and CYP2C9*3
SNP genotyping were performed using pyrosequencing as per
the manufacturer’s instructions (Biotage, Uppsala, Sweden). PCR
conditions for all the reactions together with primer and probe
sequences and restriction enzymes used for the custom-designed
assays are given in Supplementary Table 1.
Statisitcs
A multivariate Cox proportional hazards model, applying a
forward likelihood ratio, was used to assess any influence on
TTP or OS. Linkage disequilibrium was explored using a w
2
analysis. Pearson’s w
2 test was used to investigate the influence of
SNPs on each AC chemotherapy tolerance end point (using 2 2
table), unless a group contained five individuals or less, when
Fisher’s exact test was used. To standardise these data, both TTP
and OS are taken as commencing when the patient had their first
AC dose, regardless of when they were recruited to the study.
Kaplan–Meier charts and Cox regression were used to analyse and
demonstrate the influence of SNPs on TTP and OS.
RESULTS
Patient demographics
A multivariate Cox proportional hazards model, applying a forward
likelihood ratio, was used to rule out any influence on TTP or OS
from the following factors: age, ethnicity (Caucasian, South Asian or
East Asian), histological tumour type (ductal non-specific type,
lobular or other), tumour size (o20.0mm, 20.0–49.9mm or
50.0þ mm), tumour grade (I, II or III), unifocal or multifocal
disease, number of involved axillary lymph nodes (none, 1–3 or
4þ), ER status (positive or negative), PR status (positive or
negative), ERBB2 status (positive or negative). ERBB2 status was
only determined for 47 of the study participants as routine testing for
new breast cancer presentations was introduced only in late 2005,
after the date of presentation for most of our patients.
Table 2 illustrates the distribution of clinical and pathological
factors within the patient population. At a median study follow-up
of 63 months (range 1–107 months) 89% and 94% patients remain
disease free and alive, respectively. Tumour pathology demo-
graphics were representative for patients receiving AC chemo-
therapy in this era.
Of the 173 (75%) of study patients with ER-positive disease, 161
received tamoxifen for a median of 46 months. Some patients
received more than one type of hormonal modulation, because of a
switch strategy, poor drug tolerance or extended adjuvant
treatment. A total of 106 patients were treated with aromatase
inhibitors (anastrazole, letrozole or exemestane) for a median of 19
months. There was no association between either tamoxifen or AI
therapy and any of the SNPs as tested by w
2 analysis.
Genotype frequencies
The distributions of the genotypes and allelotypes are shown in
Table 3. All frequencies were in Hardy–Weinberg equilibrium and
were consistent with those seen in previously published Caucasian
populations. Linkage disequilibrium (Supplementary Table 2) was
explored using Pearson’s correlation co-efficient or a Fisher’s exact
w
2 analysis. The previously reported LD among the ABCB1 SNPs
was clearly seen, and was strongest between exon the 12 and 21
SNPs. Similarly, strong LD occurred for three of the SLC22A16
SNPs, with the A146G and T132C SNPs being in 100% LD. In
contrast, the T1226C SNP was actually in negative association with
the A146G and T132C alleles. Strong LD was also observed for the
Table 1 SNPs investigated in AC pharmacogenetics study
Gene Ref SNP ID Genotype Mutation
ABCB1
Exon 12 1128503 C1236T Synonymous
Exon 21 2032582 G2677T/A Ala893Ser/Thr
Exon 26 1045642 C3435T Synonymous
SLC22A16
Exon 2 714368 A146G His49Arg
Exon 2 6907567 T312C Synonymous
Exon 4 723685 T755C Val252Ala
Exon 5 12210538 T1226C Met409Thr
CYP2B6
*2 8192709 C64T Arg22Cys
*8 12721655 A415G Lys139Glu
*9 3745274 G516T Gln172His
*3 45482602 C777A Ser259Arg
*4 2279343 A785G Lys262Arg
*5 3211371 C1459T Arg487Cys
CYP2C9
*2 1799853 C430T Arg144Cys
*3 1057910 A1075C Ile359Leu
CYP3A5
*3 776746 A6986G Splice variant
CYP2C19
*2 4244285 G681A Splice variant
Abbreviation: AC¼doxorubicin and cyclophosphamide.
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stwo SNPs in CYP2B6 that contribute to the CYP2B6*6 allele, *4
(A785G) and *9 (G516T). There was a negative association between
the CYP2B6*5 SNP and the CYP2B6*6 SNPs.
Genotype and toxicity indicators
One aim of this study was to correlate genotypes in ABCB1,
SLC22A16, CYP2B6, CYP2C9, CYP2C19 and CYP3A5 with
tolerance of AC chemotherapy, including delivered dose intensity
and toxicity. Data were gathered retrospectively from the clinical
and chemotherapy records of 229 of the patients for the specific
end points of ‘requirement for dose delay’, ‘requirement for dose
reduction’ and ‘inability to complete planned course’. In terms of
dose delays, 21% of patients experienced at least one course of AC
chemotherapy where the timing of the cycle was delayed. Variant
carriers, compared with homozygous wild type, of the first three
linked SNPs in the SLC22A16 gene showed a statistically
significant lower incidence of AC dose delay (25% vs 13%,
P¼0.031, 25% vs 13%, P¼0.031 and 23% vs 8%, P¼0.036 for
A146G, T312C and T755C SNPs, respectively). Conversely, a
significantly greater incidence of dose delay during AC treatment
was seen in variant carriers of SLC22A16 T1226C (16% vs 28%,
P¼0.021), CYP2B6*2 (19% vs 55%, P¼0.013) and CYP2B6*5
(18% vs 29%, P¼0.053). Only 11 of the patients studied required a
dose reduction and only 14 failed to complete their prescribed
course. A lower incidence of dose reduction was associated with
the CYP2B6*9 allele (8% vs 2%, P¼0.020). There was no apparent
influence of genotype on failure to complete course. Leucopenia
and neutropenia were the most common reasons for dose delay.
Carriers of the SLC22A16 T1226C minor allele also exhibited a
higher incidence of leucopenia after the first cycle of therapy,
compared with individuals who were wild-type homozygotes,
(21% vs 6%, P¼0.004). There was no association between
genotype and leucopenia for any of the other SNPs studied.
Univariate analysis of genotype and survival
The end points used for clinical outcome measures in this study
were TTP and OS. The most recent clinical data showed that 89%
of study participants remain disease free after AC chemotherapy.
Table 3 Frequency results for AC study genotype and allelotype
Genotype frequency, n (%) Allele frequency, n (%)
wt/wt wt/v v/v wt v
ABCB1 ex12 (C1236T) 66 (29) 104 (45) 60 (26) 236 (51) 224 (49)
ABCB1 ex21 (G2677T/A) 61 (27) wt/vT¼98 (43) vT/vT¼61 (27) 224 (49) VT¼225 (49)
wt/vA¼4 (2) vA/vA¼1 (0.4) vA¼11 (2)
vT/vA¼5 (2)
ABCB1 ex26 (C3435T) 41 (18) 112 (49) 77 (34) 194 (42) 266 (58)
SLC22A16 ex2 (A146G) 147 (64) 71 (31) 12 (5) 365 (79) 95 (21)
SLC22A16 ex2 (T312C) 147 (64) 71 (31) 12 (5) 365 (79) 95 (21)
SLC22A16 ex4 (T755C) 193 (84) 36 (16) 1 (0.4) 422 (92) 38 (8)
SLC22A16 ex5 (T1226C) 130 (57) 84 (37) 16 (7) 344 (75) 116 (25)
CYP2B6*2 (C64T) 219 (95) 11 (5) 0 (0) 449 (98) 11 (2)
CYP2B6*8 (A415G) 228 (99) 2 (1) 0 (0) 458 (99.6) 2 (0.4)
CYP2B6*9 (G516T) 110 (48) 103 (45) 17 (7) 323 (70) 137 (30)
CYP2B6*3 (C777A) 230 (100) 0 (0) 0 (0) 460 (100) 0 (0)
CYP2B6*4 (A785G) 125 (54) 87 (38) 18 (8) 337 (73) 123 (27)
CYP2B6*5 (C1459T) 165 (72) 60 (26) 5 (2) 390 (85) 70 (15)
CYP2C9*2 (C430T) 165 (72) 58 (25) 7 (3) 388 (84) 72 (16)
CYP2C9*3 (A1075C) 197 (86) 33 (14) 0 (0) 427 (93) 33 (227)
CYP3A5*3 (A6986G) 1 (0.4) 32 (14) 197 (86) 34 (7) 426 (93)
CYP2C19*2 (G681A) 163 (71) 64 (28) 3 (1) 390 (85) 70 (15)
Abbreviations: AC¼doxorubicin and cyclophosphamide; wt¼wild-type alllele; v¼variant allele.
Table 2 Pharmacogenetic AC study patient demographics
Demographic n Parameters Frequency (%)
Follow-up 230 63 months (median)
Age range 230 57 years (median)
No. progressed 230 25
No. died 230 15
Ethinicity 230 European 97
South Asian 2
East Asian o1




Focality 229 Unifocal 86
Multifocal 14
Tumour grade 227 I 8
II 43
III 49
Tumour size 229 o20mm 44
20–49.9mm 51
X50mm 5
Involved nodes 230 0 63
1–3 35
X43
ER status 230 Positive 75
Negative 25
PR status 219 Positive 64
Negative 36
ERBB2 status 47 Positive 55
Negative 43
Mixed 2
Abbreviations: AC¼doxorubicin and cyclophosphamide; ER¼oestrogen receptor;
PR¼progesterone receptor.
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sCarriers of the 2677A allele (n¼10/230) for ABCB1 demon-
strated significantly shorter TTP and OS in the study population,
with hazard ratios (HR) of 4.3 (CI 1.3–14.5, P¼0.018) and 4.8 (CI
1.1–21.6, P¼0.039), respectively, when compared to wild-type
homozygotes pooled with carriers of the 2677T allele (Figure 1).
There was no difference in TTP or OS associated with the other
ABCB1 SNPs tested, nor the four SLC22A SNPs (Supplementary
Table 3).
There was a trend towards shorter TTP and OS associated with
rare allele homozygosity for the CYP2C19*2 SNP (Supplementary
Table 3). Similarly, there was a trend towards shorter TTP
associated with the CYP2B6*8 SNP (HR 6.772, CI 0.914–50.160,
n¼2/230, P¼0.06) and patients heterozygous for this SNP had a
significantly shorter OS compared with patients who were
homozygous wild type (HR 11.906, CI 1.554–91.222, P¼0.017).
However, the relevance of these data is uncertain, given the low
number of rare allele homozygotes for both SNPs (n¼3/230 and 2/
230, respectively).
SNPs within the CYP2B6 gene had the biggest impact on
outcome in the cohort. The CYP2B6*2 SNP was associated with a
shorter TTP (HR 4.646, CI 1.593–12.553, n¼11/230, P¼0.005),
but with no discernable effect on OS (Figure 2A and B). The two
highly linked CYP2B6 SNPs (*9 and *4) were also associated with a
poorer outcome (Figure 3A, B; Supplementary Table 3). In
contrast, and consistent with the greater incidence of dose delay,
there was a trend towards longer TTP in carriers of the *5 allele
(HR 0.325, CI 0.097–1.087, n¼65/320, P¼0.068; Supplementary
Table 3).
The CYP2C9*2 and *3 alleles and the CYP3A5*3 SNP had no
effect on TTP or OS (Supplementary Table 3).
Multivariate analysis of genotype and survival
The SNPs were subjected to multivariate Cox regression analysis
using a forward stepwise likelihood ratio. The statistical signifi-







































0.0 P = 0.01, log rank P = 0.022, log rank ABCB1 G/T2677A PFS ABCB1 G/T2677A OS
Time to progression (days) Survival (days)
0 500 1000 1500 2000 2500 3000 0 500 1000 1500 2000 2500 3000
Figure 1 Kaplan–Meier plots illustrating impact of MDR1 genotype on progression-free survival (A) and OS (B) of breast cancer patients treated with
adjuvant AC therapy with intention to cure. Curves are categorised according to MDR1 2677A allele carrier (dashed line) vs G2677 or 2677T allele carriers







































0.0 P = 0.002, log rank P = 0.696, log rank CYP2B6*2 PFS CYP2B6*2 OS
Time to progression (days)
0 500 1000 1500 2000 2500 3000
Survival (days)
0 500 1000 1500 2000 2500 3000
Figure 2 Kaplan–Meier illustrating impact of CYP2B6*2 genotype on progression-free survival (A) and OS (B) of breast cancer patients treated with
adjuvant AC therapy with intention to cure. Curves are categorised by heterozygotes (dashed line) vs wild-type homozygotes (solid line). Equality of survival
distribution was tested by log rank.
Pharmacogenetics of AC therapy in breast cancer
J Bray et al
1006

























sTTP and OS was retained, as was the association of the CYP2B6*8
allele with shorter OS and the CYP2B6*2 allele with shorter TTP.
DISCUSSION
The combination of doxorubicin and cyclophosphamide is widely
used as adjuvant treatment for breast cancer. As AC, these two
drugs are also important components of the FAC and ACMF
regimens. Patients selected for adjuvant treatment typically have
relatively early-stage disease and have a good probability of a
prolonged disease-free period. However, it is imperative to apply
the appropriate regimen and dosing schedule to ensure that all
patients benefit from the most effective treatment, while minimis-
ing the risk of toxicity. The recent introduction of widespread
testing for ERBB2, and prescription of trastuzumab for those
patients positive for this prognostic marker (Cobleigh et al, 1999),
has highlighted the importance of treatment individualisation.
The aim of this study was to investigate the impact of
pharmacogenetic factors on the tolerability of AC chemotherapy
and on treatment outcome, as measured by TTP and OS. As the
median follow-up in this patient group was only 62 months, there
were relatively few deaths recorded at the end of the study,
reducing the power of our study regarding this end point.
However, the most important outcome, as regards adjuvant
treatment, is TTP, as after disease recurrence, patients will usually
go on to receive other treatments, which may influence OS data.
A number of genetic variants were investigated in the breast
cancer patients studied. The target genes were selected on the basis
of their known importance for the metabolism and transport of
either doxorubicin or cyclophosphamide. For doxorubicin, the
genes most likely to influence the systemic pharmacology of this
drug are the transporters ABCB1 (Mechetner et al, 1998) and
SLC22A16 (Okabe et al, 2005). Recent papers have investigated the
importance of variations in genes that code for the carbonyl
reductase enzymes, which convert doxorubicin to doxorubicinol
(Lakhman et al, 2005). However, these investigations have been far
from conclusive and relate mainly to cardiotoxicity, which was not
an end point in our study.
For cyclophosphamide, the main interest is in those enzymes
that are responsible for metabolic activation to form 4-hydro-
xycyclophosphamide. These include CYP2B6, CYP2C9, CYP2C19,
CYP3A4 and CYP3A5. Of these, the impact of CYP3A4 on
the activation of cyclophosphamide appears to be minimal
(Chang et al, 1993; Roy et al, 1999), and despite being highly
polymorphic, the identified coding SNPs occur at a low frequency in
northern European populations similar to the population in this
study (Eiselt et al, 2001). CYP2B6 has been reported to be the major
enzyme involved in the activation of cyclophosphamide (Chang
et al, 1993). This is indirectly supported by our study, as variant
alleles of CYP2B6 had the greatest impact on disease outcome,
with CYP2B6*2, *8, *4 and *9 alleles being associated with poor
prognosis. CYP2B6*5 was associated with a greater incidence of
dose delay and may be associated with longer progression-free
survival, both of which may be indicative of a higher rate of
cyclophosphamide activation. However, though CYP2B6*2 was also
associated with dose delay, paradoxically it was associated with
shorter TTP, and this contradiction is currently unexplained.
Interpretation of these data in the context of the literature is
made complex by the inconsistent reports on the impact of
CYP2B6 SNPs on protein expression, enzymatic activity and
cyclophosphamide pharmacokinetics. CYP2B6 variants have been
associated with both decreased (Lang et al, 2001), (Jinno et al,
2003) and unchanged (Xie et al, 2003) protein expression
compared with the wild-type gene. Increased specific activity
associated with the variants has also been observed (Lang et al,
2001; Jinno et al, 2003). Similarly, though there are reports that
CYP2B6 variants confer differences in the pharmacokinetics of
cyclophosphamide (Xie et al, 2006), other studies have failed to
show a statistically significant impact (Timm et al, 2005; Nakajima
et al, 2007; Ekhart et al, 2008). Pharmacogenetic investigations into
the impact of CYP2B6 SNPs on the pharmacokinetics of other
drugs have shown fast and slow metaboliser phenotypes. For
example, the CYP2B6*9 variant has been associated with a
decreased clearance of the anti-retroviral reverse transcriptase
inhibitor efavirenz (Haas et al, 2004; Ramachandran et al, 2009).
Conversely, in a cohort of patients receiving thiotepa as therapy for
a range of solid tumours, CYP2B6*5 variant carriers had a lower
exposure to the CYP2B6 substrates, thiotepa and tepa, indicating a
fast metaboliser phenotype (Ekhart et al, 2009). Given the
inconsistencies in the literature and the low frequency of some
of the CYP2B6 SNPs investigated in this study, these results should
be treated as preliminary and require corroboration in an
independent cohort.
The CYP2C19*2 SNP results in an aberrant splice variant that
generates an alternative reading frame and a premature stop codon
(Demorais et al, 1994). The rare allele has been associated with a
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Figure 3 Kaplan–Meier plots illustrating impact of CYP2B6*4 and *9 genotype on OS of breast cancer patients treated with adjuvant AC therapy with
intention to cure. Curves are categorised by rare allele homozygotes for CYP2B6*9 (A) and CYP2B6*4 (B) (dashed lines) vs wild-type allele carriers (solid
lines). Equality of survival distribution was tested by log rank.
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swild-type allele (Timm et al, 2005) and a lower incidence of
cyclophosphamide-induced premature ovarian failure (Takada
et al, 2004). Other investigations have not observed a statistically
significant effect on cyclophosphamide pharmacokinetics asso-
ciated with the CYP2C19*2 SNP (Xie et al, 2006; Ekhart et al,
2008).Variants of the other CYP enzymes investigated in this study
had no impact on outcome or toxicity in this cohort of breast
cancer patients.
With regards to the transporters ABCB1 and SLC22A16, ABCB1
G2677T/A (‘variant A’ only) was associated with both a shorter
TTP and OS, but had no impact on dose intensity. In contrast, the
SLC22A16 T1226C was associated with a greater incidence of dose
delay and leucopenia, but had no impact on survival. In a previous
report investigating the effect of SLC22A16 genotype on doxor-
ubicin pharmacology, only a minor effect of increased exposure to
doxorubicin associated with SLC22A16 A146G rare allele homo-
zygosity was observed, and the decreased incidence of dose delay
associated with the same allele observed in this study is not
consistent with an higher systemic exposure (Lal et al, 2007).
SLC22A16 expression in cancer cells is associated with an
increased sensitivity to the cytotoxic effects of doxorubicin (Okabe
et al, 2005). Although the functional significance of the T1226C
variant form has not yet been characterised, it may be that patients
with the variant genotype are able to take up more doxorubicin
into both normal and tumour cells. This would be consistent with
the higher incidence of dose delay in the patients carrying the
variant allele. Although homozygous variants are present in less
than 10% of the population, the total proportion of carriers of the
variant allele is close to 40% and the effect seems to be maintained
in the heterozygotes.
The other SNP found to have a significant effect on TTP was the
ABCB1 G2677T/A. This non-synonymous variant results in
substitution of either serine or threonine for alanine. This SNP
has been widely studied, but the functional significance has not
consistently been demonstrated (Lal et al, 2007; Nordgard et al,
2007). The A allele is relatively rare (3% of Caucasian population,
only nine patients in this study), but the more common T allele has
been reported to result in no functional change in ABCB1 activity
(van den Heuvel-Eibrink et al, 2001) and this is reflected in the
lack of effect of the T allele on treatment outcome.
Overall, a number of SNPs appeared to influence the tolerance
and effectiveness of AC chemotherapy in this group of breast
cancer patients, however, no formal correction for multiple testing
was made and any findings should be viewed as preliminary.
Further studies would be needed to validate these findings and to
substantiate possible mechanisms.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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